Diffuse Large B Cell Lymphoma Market Overview

Following the release of our latest ebook, this is the first blog post in this series focusing on Diffuse Large B Cell Lymphoma, the most common form of Non Hodgkin Lymphoma (NHL). The DLBCL market is experiencing considerable growth; it is predicted to reach a size of almost USD 4.3 billion by 2022.

The insights shared here, and in the eBook that you can download for free , are taken from AplusA’s syndicated DLBCL market tracker. The research features insights from at least 100 US and 250 European hematologist / oncologists.

New AplusA eBook Covers the DLBCL Market

Introducing the latest eBook in our Hemato-Oncology series

Enhancing Traditional Research Methods with Social Media Listening

How do social media intelligence insights enhance your capability to make data-led business...

Primary vs Secondary Data

A thorough and agile tracking study can aid marketers to envision emerging trends, consumer...

COVID-19 INFO #4 Data Collection in 35+ Countries

This series of INFO posts is designed to keep you updated with the key developments in our...

Planning a Tracking Study: Aligning Marketing and Market Research Teams

In an increasingly competitive landscape, pharmaceutical companies are required to assess the...

French GPs React to COVID-19: AplusA Poll Wave 4

The latest results from our ongoing poll among French GPs monitoring their experiences and...

French GPs React to COVID-19: Results from AplusA Poll Wave 3

The latest results from our ongoing poll among French GPs monitoring their experiences and...

French GPs React to COVID-19: Results from AplusA Poll Waves 1 and 2

General practitioners are an essential line of defense within the healthcare system in the fight...

COVID-19 INFO #3: Data Collection and More

As the COVID-19 situation develops and as AplusA teams have been receiving questions regarding...